Biomedical papers - Ahead of Print

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. X:X | 10.5507/bp.2017.039

Effect of sertraline in paroxysmal hypertension

Jan Vaclavika, Aneta Krenkovab, Eva Kocianovaa, Tomas Vaclavikc, Monika Kamasovaa
a Deparment of Internal Medicine I - Cardiology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
b Department of Pneumology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
c Statistics and Probability Department, Faculty of Informatics and Statistics, University of Economics in Prague, nam. W. Churchilla 1938/4, 130 67 Prague, Czech Republic

Objective: Paroxysmal hypertension or pseudopheochromocytoma is quite a common problem in clinical practice. The optimal treatment for this condition has not been established. This study sought to investigate whether sertraline (a selective serotonin reuptake inhibitor) reduces the symptoms.

Methods: We enrolled 64 patients referred to our department between April 2008 and October 2014 for symptomatic paroxysmal hypertension. Patients received sertraline, 50 mg once daily, in addition to their current medication. The effect of the treatment was assessed during their next clinical visit at least 3 months later.

Results: Of the 64 patients, 57 (89%) also had sustained arterial hypertension. Mean office baseline blood pressure (BP) was 147.6/83.8 mmHg and patients used a mean of 3.1 antihypertensive drugs. Five patients did not start using sertraline and three were lost to follow-up. Of the 56 patients who started using sertraline and who came for check up, clinical improvement was observed in 42 (75%) patients - symptoms of paroxysmal hypertension fully subsided in 28 (50%) and were partially reduced in 14 (25%) . Side effects or intolerance leading to discontinuation of treatment occurred in 7 patients (12.5%). Mean office BP in patients using sertraline decreased by 12.8/7.4 mmHg (P<0.001 for both).

Conclusions: Sertraline effectively removed or reduced symptoms of paroxysmal hypertension in the majority of patients who used this treatment.

Keywords: paroxysmal hypertension, pseudopheochromocytoma, treatment, selective serotonin reuptake inhibitors, sertraline

Received: June 28, 2017; Accepted: September 6, 2017; Prepublished online: October 17, 2017


References

  1. Mann SJ. Severe paroxysmal hypertension (pseudopheochromocytoma). Curr Hypertens Rep 2008;10(1):12-8. Go to original source... Go to PubMed...
  2. Mackenzie IS, Brown MJ. Pseudopheochromocytoma. J Hypertens 2007;25(11):2204-6. Go to original source... Go to PubMed...
  3. Václavík J, Stejskal D, Lačňák B, Lazárová M, Jedelský L, Kadalová L, Janosová M, Fryšák Z, Vlček P. Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients. J Hypertens 2007;25(7):1427-31. Go to original source... Go to PubMed...
  4. Kuchel O. New Insights Into Pseudopheochromocytoma and Emotionally Provoked Hypertension. In: Clinical Hypertension and Vascular Diseases. Humana Press 2004:251-76.
  5. Fogarty J, Engel C, Russo J. Hypertension and pheochromocytoma testing: the association with anxiety disorders. Arch Fam Med 1994;3:55-60.
  6. Sharabi Y, Goldstein DS, Bentho O, Saleem A, Pechnik S, Geraci MF, Holmes C, Pacak K, Eisenhofer G. Sympathoadrenal function in patients with paroxysmal hypertension: pseudopheochromocytoma. J Hypertens 2007;25(11):2286-95. Go to original source... Go to PubMed...
  7. Mann SJ. Severe paroxysmal hypertension (pseudopheochromocytoma): understanding the cause and treatment. Arch Intern Med 1999;159(7):670-4. Go to original source... Go to PubMed...
  8. Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, Keiser HR, Pacak K. Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 2003;88(6):2656-66. Go to original source... Go to PubMed...
  9. Sawka AM, Thabane L, Gafni A, Levine M, Young WF. Measurement of fractionated plasma metanephrines for exclusion of pheochromocytoma: Can specificity be improved by adjustment for age? BMC Endocr Disord 2005;5(1):1. Go to original source... Go to PubMed...
  10. Eisenhofer G, Sharabi Y, Pacak K. Unexplained symptomatic paroxysmal hypertension in pseudopheochromocytoma: A stress response disorder? Ann N Y Acad Sci 2008;1148:469-78. Go to original source... Go to PubMed...
  11. Pickering TG, Clemow L. Paroxysmal hypertension: the role of stress and psychological factors. J Clin Hypertens (Greenwich) 2008;10(7):575-81. Go to original source... Go to PubMed...
  12. Esler M, Lambert E, Alvarenga M, Socratous F, Richards J, Barton D, Pier C, Brenchley C, Dawood T, Hastings J, Guo L, Haikerwal D, Kaye D, Jennings G, Kalff V, Kelly M, Wiesner G, Lambert G. Increased brain serotonin turnover in panic disorder patients in the absence of a panic attack: reduction by a selective serotonin reuptake inhibitor. Stress 2007;10(3):295-304. Go to original source... Go to PubMed...
  13. Därr R, Pamporaki C, Peitzsch M, Miehle K, Prejbisz A, Peczkowska M, Weismann D, Beuschlein F, Sinnott R, Bornstein SR, Neumann HP, Januszewicz A, Lenders J, Eisenhofer G. Biochemical diagnosis of phaeochromocytoma using plasma-free normetanephrine, metanephrine and methoxytyramine: importance of supine sampling under fasting conditions. Clin Endocrinol (Oxf) 2014;80(4):478-86. Go to original source... Go to PubMed...
  14. Lenders JWM, Duh Q-Y, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr; Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014;99(6):1915-42. Go to original source... Go to PubMed...
  15. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373(9665):746-58. Go to original source... Go to PubMed...
  16. Zoloft - SUMMARY OF PRODUCT CHARACTERISTICS.; 2009. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Zoloft_30/WC500007023.pdf.